- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07650214
Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic Individuals
11. juni 2026 oppdatert av: Huicui Meng, Sun Yat-sen University
This study aims to utilize a randomized controlled trial in asymptomatic hyperuricemic individuals to clarify the effects of four probiotic strains including Lactobacillus acidophilus on serum uric acid levels, pathways of uric acid synthesis, degradation and excretion, hyperuricemia-induced oxidative stress and chronic inflammatory responses, uric acid-related metabolites, gut microbiota composition and diversity.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
68
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Guangdong
-
Shenzhen, Guangdong, Kina, 518107
- Sun Yat-sen University
-
Ta kontakt med:
- Mo Lv
- Telefonnummer: 86+13538032737
- E-post: lvmo@mail2.sysu.edu.cn
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Men and women aged 18-65;
- Residents who have lived in Guangdong for more than one year;
- According to the "Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases (2023 Edition)", asymptomatic HUA is defined as a fasting serum uric acid level >420 umol /L and no history of gout symptoms such as gouty arthritis;
- Consent to be randomly assigned to the intervention or control group;
- Willing to consume the probiotic products provided by the study;
Exclusion Criteria:
- Secondary HUA caused by disease or drugs;
- Within 3 months before participating in the study, or currently taking drugs that affect uric acid metabolism, such as azathioprine, thiazide diuretics, prednisone, etc., and unwilling to stop taking them during the study;
- Taking or currently taking medication for gout within 3 months before participating in the study and unwilling to stop taking it during the study;
- Abnormal liver function (AST or ALT levels are more than 3 times the upper limit of normal), abnormal renal function (glomerular filtration rate less than 60mL/min/1.73m^2);
- Abnormal blood test results (such as white blood cell count < 3.5x10^9 /L, platelet count < 100x10^9 /L, hemoglobin < 90g/L) or other blood system diseases;
- Suffering from severe cardiovascular, kidney, gastrointestinal, hepatal, and malignant tumor diseases;
- Long-term or current use of nonsteroidal anti-inflammatory drugs, antibiotics, antihistamines, or immunomodulatory drugs, and inability to stop using these drugs within 72 hours before the start of the study;
- Currently taking anticoagulants, anabolic steroids, hydrocortisone and other hormonal drugs;
- Use of probiotic supplements within one month prior to participating in the study, and was unwilling to discontinue taking them during the study;
- Frequent use (more than once a day) of multivitamins, antioxidants, herbal supplements, dietary fiber-containing supplements, and other nutritional supplements (such as inulin, fish oil, soy lecithin, niacin, dietary fiber, flaxseed, phytoestrogens, sterols, etc.), or products containing prebiotics, probiotics, synbiotics, postbiotics, etc. (such as yogurt, fermented milk, beverages, or other fermented products) within 3 months prior to study participation, and unwilling to stop taking them;
- Self-reported weight loss of more than 7 kg or 10% in the 6 months prior to enrollment;
- Suffering from eating disorders (such as anorexia and bulimia), dysphagia, or difficulty swallowing food or medication;
- Unable to consume the probiotic products provided by the study as required during the study period;
- Drink more than 2 times a day, more than 14 times a week, and are unwilling to stop drinking during the study;
- Intolerance or food allergy related to the investigational product, drug allergy, or other issues that may affect food intake;
- Poor venous access;
- Women who have given birth in the past year, are pregnant, or plan to become pregnant within 6 months, or are breastfeeding;
- Participating or planning to participate in other dietary intervention studies, drug use studies, or cosmetic or pharmaceutical application studies in the next three months;
- Participated in clinical trials in the past 3 months;
- Any other condition that is deemed unsuitable for the trial by a physician.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebokontroll
|
Placebo (without probiotics, with other ingredients consistent with probiotic products)
|
|
Eksperimentell: Probiotic intervention
|
Probiotic products (6 × 10^9 CFU per day)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Blood uric acid
Tidsramme: Weeks 0,4,8
|
Weeks 0,4,8
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood urea nitrogen
Tidsramme: Weeks 0,4,8
|
Weeks 0,4,8
|
|
|
Blood creatinine
Tidsramme: Weeks 0,4,8
|
Weeks 0,4,8
|
|
|
Blood xanthine
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Blood hypoxanthine
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Blood xanthine oxidase
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Fecal uric acid
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Fecal allantoin
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Urine uric acid
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Urine allantoin
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Serum diamine oxidase
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Urine oxidative stress indicator level
Tidsramme: Weeks 0,8
|
Weeks 0,8
|
|
|
Blood inflammatory cytokine levels
Tidsramme: Weeks 0,8
|
Quantitative measurement of chronic inflammatory biomarkers in blood serum or plasma, such as high-sensitivity C-reactive protein (hs-CRP).
|
Weeks 0,8
|
|
Fecal gut microbiota
Tidsramme: Weeks 0,8
|
Analyzing the composition of gut microbiota using metagenomic sequencing technology.
DNA will be extracted from fecal samples using commercial kits, followed by library preparation and sequencing.
|
Weeks 0,8
|
|
Metabolomics
Tidsramme: Weeks 0,8
|
Non-targeted metabolomics using LC-MS (liquid chromatography-mass spectrometry).
|
Weeks 0,8
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. juli 2026
Primær fullføring (Antatt)
31. oktober 2027
Studiet fullført (Antatt)
31. desember 2027
Datoer for studieregistrering
Først innsendt
1. juni 2026
Først innsendt som oppfylte QC-kriteriene
11. juni 2026
Først lagt ut (Faktiske)
16. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. juni 2026
Sist bekreftet
1. mars 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SYSU PH (SZ) ME [2026] 041
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .